Abstract
In the context of OA disease, NF-κB transcription factors can be triggered by a host of stress-related stimuli including pro-inflammatory cytokines, excessive mechanical stress and ECM degradation products. Activated NF-κB regulates the expression of many cytokines and chemokines, adhesion molecules, inflammatory mediators, and several matrix degrading enzymes. NF-κB also influences the regulated accumulation and remodeling of ECM proteins and has indirect positive effects on downstream regulators of terminal chondrocyte differentiation (including β-catenin and Runx2). Although driven partly by pro-inflammatory and stress-related factors, OA pathogenesis also involves a “loss of maturational arrest” that inappropriately pushes chondrocytes towards a more differentiated, hypertrophic-like state. Growing evidence points to NF-κB signaling as not only playing a central role in the pro-inflammatory stress-related responses of chondrocytes to extra- and intra-cellular insults, but also in the control of their differentiation program. Thus unlike other signaling pathways the NF-κB activating kinases are potential therapeutic OA targets for multiple reasons. Targeted strategies to prevent unwanted NF-κB activation in this context, which do not cause side effects on other proteins or signaling pathways, need to be focused on the use of highly specific drug modalities, siRNAs or other biological inhibitors that are targeted to the activating NF-κB kinases IKKα or IKKβ or specific activating canonical NF- κB subunits. However, work remains in its infancy to evaluate the effects of efficacious, targeted NF-κB inhibitors in animal models of OA disease in vivo and to also target these strategies only to affected cartilage and joints to avoid other undesirable systemic effects.
Keywords: Cartilage, chondrocytes, homeostasis, hypertrophy, inflammation, osteoarthritis, NF-κB, IKKs
Current Drug Targets
Title: NF-κB Signaling: Multiple Angles to Target OA
Volume: 11 Issue: 5
Author(s): Kenneth B. Marcu, Miguel Otero, Eleonora Olivotto, Rosa Maria Borzi and Mary B. Goldring
Affiliation:
Keywords: Cartilage, chondrocytes, homeostasis, hypertrophy, inflammation, osteoarthritis, NF-κB, IKKs
Abstract: In the context of OA disease, NF-κB transcription factors can be triggered by a host of stress-related stimuli including pro-inflammatory cytokines, excessive mechanical stress and ECM degradation products. Activated NF-κB regulates the expression of many cytokines and chemokines, adhesion molecules, inflammatory mediators, and several matrix degrading enzymes. NF-κB also influences the regulated accumulation and remodeling of ECM proteins and has indirect positive effects on downstream regulators of terminal chondrocyte differentiation (including β-catenin and Runx2). Although driven partly by pro-inflammatory and stress-related factors, OA pathogenesis also involves a “loss of maturational arrest” that inappropriately pushes chondrocytes towards a more differentiated, hypertrophic-like state. Growing evidence points to NF-κB signaling as not only playing a central role in the pro-inflammatory stress-related responses of chondrocytes to extra- and intra-cellular insults, but also in the control of their differentiation program. Thus unlike other signaling pathways the NF-κB activating kinases are potential therapeutic OA targets for multiple reasons. Targeted strategies to prevent unwanted NF-κB activation in this context, which do not cause side effects on other proteins or signaling pathways, need to be focused on the use of highly specific drug modalities, siRNAs or other biological inhibitors that are targeted to the activating NF-κB kinases IKKα or IKKβ or specific activating canonical NF- κB subunits. However, work remains in its infancy to evaluate the effects of efficacious, targeted NF-κB inhibitors in animal models of OA disease in vivo and to also target these strategies only to affected cartilage and joints to avoid other undesirable systemic effects.
Export Options
About this article
Cite this article as:
B. Marcu Kenneth, Otero Miguel, Olivotto Eleonora, Maria Borzi Rosa and B. Goldring Mary, NF-κB Signaling: Multiple Angles to Target OA, Current Drug Targets 2010; 11 (5) . https://dx.doi.org/10.2174/138945010791011938
DOI https://dx.doi.org/10.2174/138945010791011938 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radiolabelled Oligonucleotides for Imaging of Gene Expression with PET
Current Medicinal Chemistry Drug Delivery Nanoparticles in Treating Chemoresistant Tumor Cells
Current Medicinal Chemistry In Silico Analysis of Plasmodium Falciparumenolase and Human Plasminogen Interaction: Implications for Transmission blocking of the Parasite
Letters in Drug Design & Discovery iPSCs Derived from Malignant Tumor Cells: Potential Application for Cancer Research
Current Stem Cell Research & Therapy Circulating Levels of Soluble Angiogenic Factors in Multiple Myeloma: Correlation with Parameters of Disease Activity and Prognosis
Current Angiogenesis (Discontinued) Molecular Probing and Imaging of Histone Deacetylase Inhibitors in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry The Potential of 11C-acetate PET for Monitoring the Fatty Acid Synthesis Pathway in Tumors
Current Pharmaceutical Biotechnology Voltage-Dependent Potassium Channels Kv1.3 and Kv1.5 in Human Cancer
Current Cancer Drug Targets Evaluation of Vitamin C as a Personalized Adjuvant Medicine: Pharmacogenomic Studies
Current Pharmacogenomics and Personalized Medicine Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Angiogenesis and Angiogenesis Inhibitors: a New Potential Anticancer Therapeutic Strategy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Should the Incorporation of Structural Alerts be Restricted in Drug Design? An Analysis of Structure-Toxicity Trends with Aniline-Based Drugs
Current Medicinal Chemistry Triple Negative Breast Cancer - BCL2 in Prognosis and Prediction. Review
Current Drug Targets The Ovary Feels Fine when Paracrine and Autocrine Networks Cooperate with Gonadotropins in the Regulation of Folliculogenesis
Current Pharmaceutical Design Targeting the SUMO E2 Conjugating Enzyme Ubc9 Interaction for Anti-Cancer Drug Design
Anti-Cancer Agents in Medicinal Chemistry Yin and Yang of Polyphenols in Cancer Prevention: A Short Review
Anti-Cancer Agents in Medicinal Chemistry The Novel Role for Lyn in Integrin Signaling in Human Disease
Current Signal Transduction Therapy Subclinical Thyroid Dysfunction and the Risk of Cardiovascular Disease
Current Pharmaceutical Design A Closer Look to Polyesters: Properties, Synthesis, Characterization, and Particle Drug Delivery Applications
Nanoscience & Nanotechnology-Asia Cardiovascular Tests: Use & Limits of Biochemical Markers - Therapeutic Measurements of ADMA Involved in Cardiovascular Disorders
Current Pharmaceutical Design